Shire PLC (NASDAQ:SHPG) – Equities research analysts at FBR & Co issued their Q3 2017 EPS estimates for shares of Shire PLC in a research report issued on Wednesday. FBR & Co analyst D. Buck anticipates that the biopharmaceutical company will post earnings of $3.70 per share for the quarter. FBR & Co has a “Buy” rating and a $201.00 price objective on the stock. FBR & Co also issued estimates for Shire PLC’s Q4 2017 earnings at $3.94 EPS, FY2017 earnings at $15.00 EPS, Q4 2018 earnings at $4.30 EPS, FY2018 earnings at $16.35 EPS, FY2019 earnings at $18.10 EPS and FY2020 earnings at $19.50 EPS.

Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 EPS for the quarter, missing the consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%.

WARNING: “Shire PLC Expected to Post Q3 2017 Earnings of $3.70 Per Share (SHPG)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/10/22/shire-plc-expected-to-post-q3-2017-earnings-of-3-70-per-share-shpg.html.

A number of other research firms have also weighed in on SHPG. Sanford C. Bernstein reiterated a “market perform” rating and issued a $210.00 price target on shares of Shire PLC in a research report on Thursday, July 13th. Cantor Fitzgerald reiterated a “buy” rating and issued a $222.00 price target on shares of Shire PLC in a research report on Thursday, September 14th. Zacks Investment Research lowered Shire PLC from a “hold” rating to a “sell” rating in a research report on Friday. HSBC Holdings plc upgraded Shire PLC from a “reduce” rating to a “hold” rating in a research report on Thursday, July 6th. Finally, ValuEngine lowered Shire PLC from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $219.25.

Shire PLC (NASDAQ SHPG) opened at 145.25 on Monday. The firm has a 50-day moving average of $153.97 and a 200-day moving average of $164.18. Shire PLC has a 12-month low of $139.36 and a 12-month high of $192.64. The stock has a market capitalization of $43.26 billion, a price-to-earnings ratio of 64.99 and a beta of 1.63.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Inspirion Wealth Advisors LLC raised its stake in shares of Shire PLC by 0.4% during the 2nd quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 8 shares in the last quarter. Synovus Financial Corp raised its stake in shares of Shire PLC by 0.4% during the 2nd quarter. Synovus Financial Corp now owns 2,780 shares of the biopharmaceutical company’s stock worth $458,000 after purchasing an additional 11 shares in the last quarter. Baldwin Investment Management LLC raised its stake in shares of Shire PLC by 1.4% during the 2nd quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 23 shares in the last quarter. Hartford Financial Management Inc. raised its stake in shares of Shire PLC by 5.4% during the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 32 shares in the last quarter. Finally, American International Group Inc. raised its stake in shares of Shire PLC by 1.2% during the 1st quarter. American International Group Inc. now owns 4,607 shares of the biopharmaceutical company’s stock worth $803,000 after purchasing an additional 54 shares in the last quarter. 19.24% of the stock is owned by institutional investors.

The company also recently declared a semiannual dividend, which was paid on Friday, October 20th. Stockholders of record on Friday, September 8th were paid a dividend of $0.1527 per share. This represents a dividend yield of 0.21%. The ex-dividend date of this dividend was Thursday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 41.07%.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Earnings History and Estimates for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.